Novartis Access – measuring the impact

Professor Richard Laing, an expert on access-to-medicine programs, says the pharma industry needs to better measure the impact of our programs. So we’ve asked him to scrutinize our own Novartis Access program.

To learn more visit: http://socialbusiness.novartis.com

© 2017 Novartis AG